- In November 2022, A clinical trial of Tree MATA MPL or Tree MATA immunotherapy for allergic rhinitis and type I hypersensitivity was terminated due to insufficient subject enrollment. Sponsored by Allergy Therapeutics, known for subcutaneous and sublingual immunotherapy, the trial aimed to explore new treatments but faced challenges in recruiting participants
- In November 2020, Dr. Reddy's Laboratories announced plans to acquire several brands from Glenmark Pharmaceuticals, including Momat Rino and Glenspray variants, pending final approvals and procedural steps across Russia, Kazakhstan, Uzbekistan, and Ukraine
- In May 2021, Glenmark Pharmaceuticals launched Ryaltris nasal spray in India, expanding treatment options for moderate to severe allergic rhinitis. This initiative aimed to enhance growth prospects in the allergic rhinitis sector, providing a new therapeutic option for patients in the region
- In April 2021, ALK received FDA approval for its short ragweed pollen allergen extract, designed for patients aged 5 to 65 with short ragweed pollen-induced allergic rhinitis. This milestone marked a significant advancement in expanding treatment options for seasonal allergies in the United States
